Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Raul Mostoslavsky
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Galilei Biosciences Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Mostoslavsky is a co-founder of Galilei Biosciences Inc. with equity in the private company. Galilei Biosciences Inc. seeks to develop activators of the mammalian SIRT6 protein. The research projects identified above investigate the role of SIRT6 in colon cancer and pancreatic cancer, which could provide a putative therapeutic approach to tackle cancer development in these areas, and test whether SIRT6 regulates activation of metabolic and developmental genes through a novel, previously unrecognized mechanism of action, which may inform treatment against developmental diseases, metabolic diseases and cancer. The results of these research projects could therefore be of interest to the company.
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
Pancreatic cancer is the most lethal adult malignancy in the US due in large part to the propensity to metastasize. Our previous work has implicated Lin28b as a major developmental gene involved in the progression and metastasis of pancreatic cancer. This project aims to mechanistically characterize the role of Lin28b in pancreatic cancer through model systems and from analysis of human blood and tissue from pancreatic cancer patients.
Filed on June 25, 2019.
Tell us what you know about Raul Mostoslavsky's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Raul Mostoslavsky filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Raul Mostoslavsky | Massachusetts General Hospital | Conflict of Interest | Galilei Biosciences Inc. | Value cannot be readily determined |
| Raul Mostoslavsky | Massachusetts General Hospital | Conflict of Interest | Galilei Biosciences, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.